Public Meeting on Functional GI Disorders Patient-Focused Drug Development

On May 22, 2015, the FDA obtained patient input on the impact of functional GI disorders on daily life and patients’ views on currently available therapies to treat the functional GI disorders, such as irritable bowel syndrome, gastroparesis, chronic persistent symptomatic gastroesophageal reflux despite standard therapeutic interventions, and chronic idiopathic constipation.  G-PACT was there!

For those who were unable to attend or participate via the webcast, the meeting was recorded and may be viewed here:

Part 1:

https://collaboration.fda.gov/p3xfprr0hlr/?launcher=false&fcsContent=true&pbMode=normal

Part 2:  https://collaboration.fda.gov/p5lp2oxt3wy/?launcher=false&fcsContent=true&pbMode=normal

To read the transcript of the meeting, go to  http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM448905.pdf